TC
CRSP icon

Torno Capital’s CRISPR Therapeutics CRSP Stock Holding History

Torno Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,000
Closed -$730K – 81
2025
Q2 		$730K Buy
+15,000
New +$580K 0.13% 50

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Torno Capital's CRSP Position: Q2 2024 in Review

Torno Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 20,000 shares — an estimated $1.36M sold.

Torno Capital first reported a position in CRSP in Q4 2023 and held it in 2 quarters. The position peaked at $1.36M in Q1 2024. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Torno Capital reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Torno Capital sold 20,000 CRISPR Therapeutics shares in Q2 2024, an estimated $1.36M.
  • Torno Capital first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 2 quarters.
  • Torno Capital's CRISPR Therapeutics position peaked at $1.36M in Q1 2024.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Torno Capital's 13F filing for Q2 2024, filed 14 Aug 2024.